Todos Medical Announces ANVISA Authorization in Br
Post# of 30027
JULY 16, 2020 7:00AM EDT
REHOVOT, Israel, NEW YORK and Shanghai, July 16, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced that its partner supplier 3D Medicines Corporation (3D Med) has received authorization from the Brazilian Health Surveillance Agency (ANVISA) to distribute its COVID-19 qPCR test kits and ANDis extraction systems.
On July 10, 2020, Todos Medical announced the expansion of its agreement with 3D Med to include COVID-19 testing product distribution rights in multiple international markets including Brazil, as well as in the U.S.
For information related to Todos Medical’s COVID-19 testing capabilities, please visit www.todoscovid19.com.
For testing and PPE inquiries, please email sales@todosmedical.com
https://investor.todosmedical.com/news-events...brazil-for